Oakrum pharma and ani pharmaceuticals announce the launch of betaine anhydrous powder, the first generic version of cystadane® (betaine anhydrous for oral solution) powder, including 180 days of exclusivity

Saint louis, feb. 14, 2022 /prnewswire/ -- oakrum pharma, llc ("oakrum pharma"), in collaboration with ani pharmaceuticals (nasdaq: anip), announce that the u.s. food and drug administration (fda) has approved the abbreviated new drug application (anda) for a generic version of cystadane®1 (betaine anhydrous for oral solution) powder in a 180 gm bottle and granted competitive generic therapy (cgt) of 180 days of exclusivity.  shipments of the generic product began in early february, 2022.
ANIP Ratings Summary
ANIP Quant Ranking